Literature DB >> 24237433

[Determination of hepatitis C virus genotypes among hepatitis C patients in Eastern Black Sea Region, Turkey].

Celal Kurtuluş Buruk1, Gülçin Bayramoğlu, Ahu Reis, Neşe Kaklıkkaya, Ilknur Tosun, Faruk Aydın.   

Abstract

Hepatitis C virus (HCV), the major cause of transfusion-associated hepatitis, is an important public health problem in the world as well as in Turkey. HCV is grouped as six distinct genotypes and a large number of closely-related subtypes. Genotyping of HCV is an important tool for providing epidemiological data, prediction of prognosis, and optimization of antiviral therapy. This study was carried out to determine the distribution of HCV genotypes in hepatitis C patients residing in different provinces of the Eastern Black Sea Region, Turkey. A total of 304 HCV-RNA positive cases (151 male, 153 female; age range: 11-93 years, mean age: 55.2 ± 13.3 years) who were admitted to the Molecular Microbiology Unit of Department of Medical Microbiology, Karadeniz Technical University Faculty of Medicine, between January 2009 to December 2012, were included in the study. HCV genotypes were detected in plasma samples of the patients by using commercial assays [INNO-LiPA HCV II (Innogenetics, Belgium) or Abbott RealTime HCV Genotype II (Abbott Molecular Inc, USA)]. Due to the ambiguous genotyping results in some samples with these methods, an in-house multiplex polymerase chain reaction (PCR) assay with genotype-specific primers was also used in the study. Similar to the previous reports from Turkey, our results showed that four HCV genotypes (1, 2, 3, and 4) prevailed in the Eastern Black Sea Region and the predominant genotype and subtype were genotype 1 (92.8%) and 1b (87.5%), respectively. Distribution of genotypes were observed to vary according to the province. Prevalences of subtype 1a, genotype 2, 3, and 4 were noted as 5.3%, 1.6%, 4.9%, and 0.7%, respectively. Furthermore, the samples from Giresun, Gumushane and Bayburt provinces, which are relatively less immigrated, had higher genotype 1, and the prevalence rates in the region was affected by the presence of non-citizen residents. This study is the first report on distribution of HCV genotypes in chronic hepatitis C patients living in the provinces of Eastern Black Sea Region. Moreover, genotype-specific multiplex PCR assay could be useful in resolving certain methodological problems such as "ghost bands" encountered in line probe assay (LiPA) and multiple genotypes (including genotype 4) observed in real-time PCR during the characterization of HCV genotypes seen in Turkey.

Entities:  

Mesh:

Year:  2013        PMID: 24237433     DOI: 10.5578/mb.5796

Source DB:  PubMed          Journal:  Mikrobiyol Bul        ISSN: 0374-9096            Impact factor:   0.622


  3 in total

1.  Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study.

Authors:  Yunus Gürbüz; Necla Eren Tülek; Emin Ediz Tütüncü; Süda Tekin Koruk; Bilgehan Aygen; Neşe Demirtürk; Sami Kınıklı; Ali Kaya; Taner Yıldırmak; Kaya Süer; Fatime Korkmaz; Onur Ural; Sıla Akhan; Özgür Günal; Nazan Tuna; Şükran Köse; İbak Gönen; Bahar Örmen; Nesrin Türker; Neşe Saltoğlu; Ayşe Batırel; Günay Tuncer; Cemal Bulut; Fatma Sırmatel; Asım Ulçay; Ergenekon Karagöz; Derviş Tosun; Alper Şener; Aynur Aynıoğlu; Elif Sargın Altunok
Journal:  Balkan Med J       Date:  2016-01-01       Impact factor: 2.021

2.  Changes on Hepatitis C virus genotype distribution in Western Turkey: Evaluation of twelve-year data.

Authors:  Alev Çetin Duran; Özgül Kaya Çetinkaya; Ayça Arzu Sayıner; Gülşah Şeydaoğlu; Emre Özkarataş; Hakan Abacıoğlu
Journal:  Turk J Gastroenterol       Date:  2020-02       Impact factor: 1.852

3.  Distribution and predominance of genotype 3 in hepatitis C virus carriers in the province of kahramanmaras, Turkey.

Authors:  Ahmet Caliskan; Ozlem Kirisci; Esra Ozkaya; Sevinc Ozden; Seray Tumer; Serkan Caglar; Selma Ates Guler; Hande Senol
Journal:  Hepat Mon       Date:  2015-04-25       Impact factor: 0.660

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.